Therapeutic Asset Ratings
423 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Gensci139
Cancer
Changchun GeneScience Pharmaceutical Co., Ltd.
P1
C
(36)
Gensci140 For
Cancer
Changchun GeneScience Pharmaceutical Co., Ltd.
P1
C
(36)
Gensci143 For
Cancer
Changchun GeneScience Pharmaceutical Co., Ltd.
P1
C
(36)
gh2616 tablets
Cancer
Suzhou Genhouse Bio Co., Ltd.
P1
C
(36)
gs-0201
Cancer
Gilead Sciences
P1
C
(36)
gs-2121
Cancer
Gilead Sciences
P1
C
(36)
gs-2426
Cancer
Gilead Sciences
P1
C
(36)
Hbt-708
Cancer
Shenyang Sunshine Pharmaceutical Co., LTD.
P1
C
(36)
hdm2005
Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
P1
C
(36)
hdm2006
Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
P1
C
(36)
hdm2017
Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
P1
C
(36)
hdm2024
Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
P1
C
(36)
Hemay181
Cancer
Ganzhou Hemay Pharmaceutical Co., Ltd
P1
C
(36)
Hrs-3802
Cancer
Shandong Suncadia Medicine Co., Ltd.
P1
C
(36)
Hrs-4508
Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1
C
(36)
Hrs-6209
Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1
C
(36)
Hrxg-K-1939
Cancer
Fudan University
P1
C
(36)
hs-20117
Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(36)
hs-20122
Cancer
Hansoh BioMedical R&D Company
P1
C
(36)
hsk41959
Cancer
Haisco Pharmaceutical Group Co., Ltd.
P1
C
(36)
hv-101
Cancer
Hervor Therapeutics
P1
C
(36)
hw071021 tablets
Cancer
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
P1
C
(36)
hws116
Cancer
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
P1
C
(36)
Ibi 389
Cancer
Innovent Biologics (Suzhou) Co. Ltd.
P1
C
(36)
imm27m
Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
P1
C
(36)
Showing 276 to 300 of 423 assets
Previous
Page 12 of 17
Next
